5 million patient samples with its proprietary RxGuardian offering to health care companions viagradanmark.eu more info . ‘We’re proud to reach these milestones through the work of dedicated staff inside our Greensboro and Midland labs and Baltimore headquarters, growing our science-based technology, enhancing service to our physician partners and buying meeting our clients’ needs,’ stated Ancelmo Lopes, CEO of Ameritox. By adding to your body of knowledge regarding managing individuals on chronic opioid therapy, Ameritox continues to assist physicians to make better treatment decisions. During the past two years, nine key studies have been accepted for or offered at national clinical meetings.
.. Roche and Amgen end EPO patent infringement dispute Amgen announced today that the United States District Courtroom in Boston provides entered last judgment and a long term injunction against Roche prohibiting Roche from infringing Amgen’s patents on recombinant erythropoietin , thus bringing the five-yr patent infringement dispute to a finish. Today’s judgment was accompanied by Roche’s admission that the five Amgen EPO patents mixed up in lawsuit are valid, enforceable and infringed by Roche’s pegylated-erythropoietin product, MIRCERA and by Amgen enabling Roche to begin selling MIRCERA in the U.S.